心房颤动患者非维生素K拮抗剂口服抗凝药实验室监测的综述
本综述探讨了非维生素K拮抗剂口服抗凝药(NOAC)在心房颤动患者中固定剂量给药无需常规监测的药理学基础,分析了药物水平测量与解读的复杂性,并评估了常规实验室监测在NOAC治疗管理中的作用。结论指出,未经监测的NOAC治疗至少与监测下的华法林同样有效且安全,进一步研究需确定常规监测是否能带来净获益,在此之前临床医生应继续以固定剂量处方NOAC而不进行常规监测。
要点
- NOAC固定剂量给药无需常规凝血监测,随机试验表明其疗效与安全性至少不劣于剂量调整华法林。
- 尽管可准确测量NOAC药物水平,但患者内变异及年龄、肾功能等混杂因素使结果解读复杂。
- 尚缺乏特定人群最佳药物水平、剂量调整及常规监测改善结局的证据,当前应继续固定剂量不监测。
核心结论
- 来自心房颤动患者随机接受NOAC或华法林的稳健证据表明,未经监测的NOAC治疗至少与监测下的华法林同样有效且安全,颅内出血率更低且死亡率降低。
- 需要进一步研究以确定常规实验室监测是否可能为患者提供净获益;在获得此类数据之前,临床医生应继续以固定剂量处方NOAC而不进行常规监测。
研究设计与样本
- 本综述 examination 了抗凝监测的历史基础,讨论了测量和解读药物水平的方法,并批判性评估了常规实验室监测在NOAC治疗管理中的作用。
主要发现
- NOAC可预测的抗凝反应为其固定剂量给药无需常规凝血监测提供了药理学基础。
- 尽管可以准确测量NOAC药物水平,但患者内变异使这些结果的解读复杂化。
- 患者特征如年龄和肾功能混杂了NOAC药物水平与临床结局之间的关联。
- 尚缺乏关于特定患者群体(如老年人、肾功能受损者及高出血风险者)最佳药物水平、达到预期水平的适当剂量调整以及常规实验室监测和剂量调整是否改善临床结局的信息。
- 包含常规治疗药物监测和剂量调整的管理策略相对于当前不包含此类监测的标准治疗指标的获益尚未被证实。
局限性
- 患者内变异使NOAC药物水平的解读复杂化。
- 患者特征如年龄和肾功能混杂了NOAC药物水平与临床结局之间的关联。
- 尚缺乏关于特定患者群体最佳药物水平、适当剂量调整以及常规监测和剂量调整是否改善临床结局的信息。
- 包含常规治疗药物监测和剂量调整的管理策略相对于当前标准治疗指标的获益尚未被证实。
- 需要进一步研究以确定常规实验室监测是否可能为患者提供净获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The non-vitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are administered in fixed doses without anticoagulant monitoring. Randomized trials show that unmonitored NOAC therapy is at least as effective as and safer than dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Subgroup analyses indicate that plasma drug levels or anticoagulant activity of the NOACs predict stroke and bleeding. This review examines the historical basis for anticoagulant monitoring, discusses methods to measure and interpret drug levels, and critically assesses the role of routine laboratory monitoring in the management of NOAC therapy. OBSERVATIONS: The predictable anticoagulant response of NOACs has provided the pharmacological basis for their administration in fixed doses without routine coagulation monitoring. Although it is possible to accurately measure NOAC drug levels, within-patient variability complicates interpretation of these results. Furthermore, patient characteristics, such as age and renal function, confound the association between NOAC drug levels and clinical outcomes. Information is lacking on the optimal drug level in particular patient groups (eg, elderly, the renally impaired, and those with high bleeding risk), the appropriate dose adjustment to achieve expected levels, and whether routine laboratory monitoring and dose adjustment will improve clinical outcomes. A benefit of a management strategy that incorporates routine therapeutic drug monitoring and dose adjustment over current standard-of-care metrics without such monitoring remains unproven. CONCLUSIONS AND RELEVANCE: Robust evidence from patients with atrial fibrillation randomized to NOACs or warfarin demonstrates that unmonitored NOAC therapy is at least as effective and safe as monitored warfarin, with lower rates of intracranial hemorrhage and reduced mortality. Further research is required to determine whether routine laboratory monitoring might provide a net benefit for patients. Until such data are available, clinicians should continue to prescribe NOACs in fixed doses without routine monitoring.
引用
- Eikelboom JW, Quinlan DJ, Hirsh J, et al. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017. PMID: 28355459. doi:10.1001/jamacardio.2017.0364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。